MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers

Zearo, Silvia; Kim, Edward; Zhu, Ying; Zhao, Jing; Sidhu, Stan; Robinson, Bruce G.; Soon, Patsy S.

doi:10.1186/1471-2407-14-200

Cited by 74 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-484 has been identified to be increased in the serum of patients with breast and pancreatic cancer (37). The present results revealed that miR-484 exhibited a 29.7-fold-change in expression in patients with HCC compared with the healthy control.…”

Section: Discussionsupporting

confidence: 47%

“…The remaining 11 miRNAs have never been studied in liver cancer (Table III). Among the 11 differentially dysregulated miRNAs, the function of miR-374a, miR-188-5p, miR-1183, miR-454, miR-324-3p, miR-484, miR-3188, and miR-216b have been studied in human cancers (27,(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43); however, the exact function of miR-4271, miR-1471 and miR-3610 remains unclear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA expression profiling in patients with hepatocellular carcinoma of familial aggregation and hepatitis B virus infection

Zhang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Numerous studies have suggested that microRNAs (miRNAs) potently affect hepatocarcinogenesis. However, the miRNA expression profiling in patients with hepatocellular carcinoma (HCC) of familial aggregation and hepatitis B virus (HBV) infection has not been elucidated. In the present study, the plasma miRNA expression profiles of 3 patients with HCC with familial aggregation of HCC and HBV infection and 1 healthy volunteer were examined by microarray analysis, in order to identify relevant miRNAs involved in the pathogenesis of HCC with familial aggregation and HBV infection. The results indicated that 26 miRNAs exhibited a ≥20-fold increase or decrease in the plasma of patients with HCC, compared with the healthy control (24 upregulated and 2 downregulated). Among these altered miRNAs, 15 of them have been reported in HCC. The other 11 miRNAs have never been reported in HCC. These differentially-expressed miRNAs may be potential molecular markers for HCC pathogenesis and development.

show abstract

Section: Discussionsupporting

confidence: 47%

Section: Discussionmentioning

confidence: 99%

MicroRNA expression profiling in patients with hepatocellular carcinoma of familial aggregation and hepatitis B virus infection

Zhang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…However, previous studies on serum miRNAs have not provided a standardized internal standard. A number of studies have used miR-16 as a standardized internal control for serum miRNA experiments (18,19), however, the expression of serum miR-16 is not stable in a number of tumors (20). Furthermore, in miR-16 derived from red blood cells, the occurrence of hemolysis would result in 20-30-fold increase in blood miR-16, which would affect the results (21).…”

Section: A B C Dmentioning

confidence: 99%

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The purpose of the present study was to investigate the serum levels of microRNA (miRNA/miR)-382-3p, -598-3p, -1246 and -184 in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Serum samples were obtained from 100 breast cancer patients and 40 age-matched healthy control subjects in Taizhou Central Hospital (Taizhou, Zhejiang, China) between January 2013 and September 2014. The serum expression levels of miR-382-3p, -598-3p, -1246 and -184 were determined by stem-loop reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curves were drawn to evaluate the sensitivity and specificity of the serum miRNA expression levels for the screening of breast cancer. miR-382-3p and -1246 were significantly upregulated in the serum of the breast cancer patients, while miR-598-3p and -184 were significantly downregulated. The sensitivity and specificity to detect breast cancer were as follows: miR-382-3p, 52.0 and 92.5%; miR-598-3p, 95.0 and 85.0%; miR-1246, 93.0 and 75.0%; and miR-184, 87.5 and 71.0%, respectively. The expression levels of the four serum miRNAs were not correlated with the patients' clinical stage. In summary, miR-382-3p, -598-3p, -1246 and -184 are all involved in the development of breast cancer, and are promising biomarkers for breast cancer detection. IntroductionBreast cancer has become the most common cancer in women in China, accounting for 12.2% of all newly diagnosed breast cancers and 9.6% of all mortalities from breast cancer worldwide (1). Early detection of breast cancer is the key to successful treatment and patient survival. Mammographies, magnetic resonance imaging and ultrasound are being used for the screening of breast cancer, but these techniques have limitations such as low sensitivity and specificity (2). Finding effective biomarkers is vital for the screening of breast cancer.MicroRNAs (miRNAs/miRs) are a group of small non-coding RNAs (3), which can bind to the 3' untranslated region (UTR), the 5' UTR (4) or the coding region (5) of target mRNA. miRNAs play important roles in the negative regulation of gene expression in a post-transcriptional manner, and are involved in a number of signal transduction pathways, including cell proliferation, differentiation, apoptosis, immune response and angiogenesis (6). Previous studies have revealed the abnormal expression of miRNAs in the development and progression of breast cancer (7), and miRNAs are closely linked with tumor-associated signal transduction pathways (8). In our previous study, 10 miRNAs that were significantly differentially expressed were found by the second generation of high-throughput sequencing technology, Illumina Hiseq2500 (9). In the present study, 4 miRNAs, miR-382-3p, -598-3p, -1246 and -184, were further investigated. The purpose of this study was to investigate the serum levels of these miRNAs in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Materials and methods Subje...

show abstract

“…Generally, the 382-well format is the most developed for its reduced costs, high throughput, and simple workflow. Moreover, its high sensibility allows the use of a low input of RNA (1-500 ng) [33,34]. Another platform used for miRNAs profile is Microarray technology.…”

Section: Circulating Micrornamentioning

confidence: 99%

Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs

Castiglia¹,

Pérez²,

Serrano

et al. 2017

Current Clinical Pathology

View full text Add to dashboard Cite

MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers

Cited by 74 publications

References 27 publications

MicroRNA expression profiling in patients with hepatocellular carcinoma of familial aggregation and hepatitis B virus infection

MicroRNA expression profiling in patients with hepatocellular carcinoma of familial aggregation and hepatitis B virus infection

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs

Contact Info

Product

Resources

About